Hiroshi Miyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroshi Miyama has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Seiji Takatsuki
Department of Cardiology Keio University School of Medicine Tokyo Japan
7 shared publications - Keiichi Fukuda
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
5 shared publications - Takehiro Kimura
Keio University School of Medicine
4 shared publications Yoshinori Katsumata
Department of Cardiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
4 shared publications- Yoshinori Katsumata
Institute for Integrated Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
4 shared publications Koki Yamaoka
Department of Cardiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
3 shared publications
Latest Publications
- 8 April 2024
- Published by Elsevier in Heart Rhythm
- Vol. 21 (9) , 1469-1476
Predictors and incidence of health status deterioration in patients with early atrial fibrillation
- 8 April 2024
- Published by Elsevier in Heart Rhythm
- Vol. 21 (9) , 1469-1476
Predictors and incidence of health status deterioration in patients with early atrial fibrillation
- Open Access
- 19 December 2023
- Published by Elsevier in Heart Rhythm O2
- Vol. 5 (2) , 97-102
Assessment of patient characteristics influencing the complexity of leadless pacemaker implantation
- 19 December 2023
- Published by Elsevier in Heart Rhythm O2
- Vol. 5 (2) , 97-102
Open AccessAssessment of patient characteristics influencing the complexity of leadless pacemaker implantation
- Open Access
- 15 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7712
Discontinuation of Oral Anticoagulants in Atrial Fibrillation Patients: Impact of Treatment Strategy and on Patients’ Health Status
Aims: The discontinuation of oral anticoagulants (OACs) remains as a significant concern in the management of atrial fibrillation (AF). The discontinuation rate may vary depending on management strategy, and physicians may also discontinue OACs due to concerns about patient satisfaction with their care. We aimed to assess the incidence of OAC discontinuation and its relationship to patients’ health in an outpatient AF registry. Methods and Results: From a multicenter registry for newly recognized AF patients (n = 3313), we extracted 1647 (49.7%) patients with OACs and a CHA2DS2-Vasc score of ≥2. Discontinuation was defined as sustained cessation of OACs within a 1-year follow-up. We examined predictors associated with discontinuation and its relations to health status defined by the AFEQT questionnaire. Of the 1647 patients, 385 (23.6%) discontinued OACs after 1 year, with discontinuation rates varying across treatment strategies (15.3% for catheter ablation, 4.9% for rhythm control with antiarrhythmic drugs, and 3.0% for rate control). Successful rhythm control was associated with discontinuation in the catheter ablation (OR 6.61, 95% CI 3.00–14.6, p < 0.001) and antiarrhythmic drugs (OR 6.47, 95% CI 2.62–15.9, p < 0.001) groups, whereas the incidence of bleeding events within 1 year was associated with discontinuation in the rate control group. One-year AFEQT scores did not significantly differ between patients who discontinued OACs and those who did not in each treatment strategy group. Conclusions: OAC discontinuation was common among AF patients with significant stroke risk but varied depending on the chosen treatment strategy. This study also found no significant association between OAC discontinuation and patients’ health status.
- 15 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7712
Open AccessDiscontinuation of Oral Anticoagulants in Atrial Fibrillation Patients: Impact of Treatment Strategy and on Patients’ Health Status
Aims: The discontinuation of oral anticoagulants (OACs) remains as a significant concern in the management of atrial fibrillation (AF). The discontinuation rate may vary depending on management strategy, and physicians may also discontinue OACs due to concerns about patient satisfaction with their care. We aimed to assess the incidence of OAC discontinuation and its relationship to patients’ health in an outpatient AF registry. Methods and Results: From a multicenter registry for newly recognized AF patients (n = 3313), we extracted 1647 (49.7%) patients with OACs and a CHA2DS2-Vasc score of ≥2. Discontinuation was defined as sustained cessation of OACs within a 1-year follow-up. We examined predictors associated with discontinuation and its relations to health status defined by the AFEQT questionnaire. Of the 1647 patients, 385 (23.6%) discontinued OACs after 1 year, with discontinuation rates varying across treatment strategies (15.3% for catheter ablation, 4.9% for rhythm control with antiarrhythmic drugs, and 3.0% for rate control). Successful rhythm control was associated with discontinuation in the catheter ablation (OR 6.61, 95% CI 3.00–14.6, p < 0.001) and antiarrhythmic drugs (OR 6.47, 95% CI 2.62–15.9, p < 0.001) groups, whereas the incidence of bleeding events within 1 year was associated with discontinuation in the rate control group. One-year AFEQT scores did not significantly differ between patients who discontinued OACs and those who did not in each treatment strategy group. Conclusions: OAC discontinuation was common among AF patients with significant stroke risk but varied depending on the chosen treatment strategy. This study also found no significant association between OAC discontinuation and patients’ health status.
- Open Access
- 19 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (18) , e029321
Prognostic Implications and Efficacy of Catheter Ablation by Atrial Fibrillation Type
Background: Catheter ablation (CA) for atrial fibrillation (AF) is preferred for paroxysmal AF (PAF) but selectively performed in patients with persistent AF (PersAF). This study aimed to investigate the prognostic differences and consequences of CA based on the AF type. Methods and Results: Data from a multicenter AF cohort study were analyzed, categorizing patients as PAF or PersAF according to AF duration (≤7 or >7 days, respectively). A composite of all‐cause death, heart failure hospitalization, stroke, and bleeding events during 2‐year follow‐up and changes in the Atrial Fibrillation Effect on Quality‐of‐life score were compared. Additionally, propensity score matching was performed to compare clinical outcomes of patients with and without CA in both AF types. Among 2788 patients, 51.6% and 48.4% had PAF and PersAF, respectively. Patients with PersAF had a higher incidence of the composite outcome (12.8% versus 7.2%; P P =0.031) and was associated with poor improvements in Atrial Fibrillation Effect on Quality‐of‐life scores. Propensity score matching analysis showed that the CA group had significantly fewer adverse events than the medication group among patients with PAF (odds ratio, 0.31 [95% CI, 0.18–0.68]; P =0.002). Patients with PersAF showed a similar but nonsignificant trend. Conclusions: PersAF is a risk factor for worse clinical outcomes, including patients' health status. CA is associated with fewer adverse events, although careful consideration is required based on the AF type.
- 19 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (18) , e029321
Open AccessPrognostic Implications and Efficacy of Catheter Ablation by Atrial Fibrillation Type
Background: Catheter ablation (CA) for atrial fibrillation (AF) is preferred for paroxysmal AF (PAF) but selectively performed in patients with persistent AF (PersAF). This study aimed to investigate the prognostic differences and consequences of CA based on the AF type. Methods and Results: Data from a multicenter AF cohort study were analyzed, categorizing patients as PAF or PersAF according to AF duration (≤7 or >7 days, respectively). A composite of all‐cause death, heart failure hospitalization, stroke, and bleeding events during 2‐year follow‐up and changes in the Atrial Fibrillation Effect on Quality‐of‐life score were compared. Additionally, propensity score matching was performed to compare clinical outcomes of patients with and without CA in both AF types. Among 2788 patients, 51.6% and 48.4% had PAF and PersAF, respectively. Patients with PersAF had a higher incidence of the composite outcome (12.8% versus 7.2%; P P =0.031) and was associated with poor improvements in Atrial Fibrillation Effect on Quality‐of‐life scores. Propensity score matching analysis showed that the CA group had significantly fewer adverse events than the medication group among patients with PAF (odds ratio, 0.31 [95% CI, 0.18–0.68]; P =0.002). Patients with PersAF showed a similar but nonsignificant trend. Conclusions: PersAF is a risk factor for worse clinical outcomes, including patients' health status. CA is associated with fewer adverse events, although careful consideration is required based on the AF type.
- Open Access
- 3 July 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (7)
Delineation of conduction gaps of linear lesions during atrial fibrillation ablation using ultra-high-density mapping
Linear lesions are routinely created by radiofrequency catheter ablation. Unwanted electrical conduction gaps can be produced and are often difficult to ablate. This study aimed to clarify the characteristics of conduction gaps during atrial fibrillation ablation by analysing bidirectional activation maps using a high-density mapping system (RHYTHMIA). This retrospective study included 31 patients who had conduction gaps along pulmonary vein (PV) isolation or box ablation lesions. Activation maps were sequentially created during pacing from the coronary sinus and PV to reveal the earliest activation site, defined by the entrance and exit. The locations, length between the entrance and exit (gap length), and direction were analysed. Thirty-four bidirectional activation maps were drawn: 21 were box isolation lesions (box group), and 13 were PV isolation lesions (PVI group). Among the box group, nine conduction gaps were present in the roof region and 12 in the bottom region, while nine in right PV and four in left PV among the PVI group. Gap lengths in the roof region were longer than those in the bottom region (26.8 ± 11.8 vs. 14.5 ± 9.8 mm; P = 0.022), while those in right PV tended to longer than those in left PV (28.0 ± 15.3 vs. 16.8 ± 8.0 mm, P = 0.201). The entrances and exits of electrical conduction gaps were separated, especially in the roof region, indicating that epicardial conduction might contribute to gap formation. Identifying the bidirectional conduction gap might indicate the location and direction of epicardial conduction. Bidirectional activation maps for conduction gap at roof and bottom are shown. The length between the entrance and exit (gap length) is longer at roof line than bottom line (26.8 ± 11.8 vs. 14.6 ± 9.8 mm, P = 0.022).
- 3 July 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (7)
Open AccessDelineation of conduction gaps of linear lesions during atrial fibrillation ablation using ultra-high-density mapping
Linear lesions are routinely created by radiofrequency catheter ablation. Unwanted electrical conduction gaps can be produced and are often difficult to ablate. This study aimed to clarify the characteristics of conduction gaps during atrial fibrillation ablation by analysing bidirectional activation maps using a high-density mapping system (RHYTHMIA). This retrospective study included 31 patients who had conduction gaps along pulmonary vein (PV) isolation or box ablation lesions. Activation maps were sequentially created during pacing from the coronary sinus and PV to reveal the earliest activation site, defined by the entrance and exit. The locations, length between the entrance and exit (gap length), and direction were analysed. Thirty-four bidirectional activation maps were drawn: 21 were box isolation lesions (box group), and 13 were PV isolation lesions (PVI group). Among the box group, nine conduction gaps were present in the roof region and 12 in the bottom region, while nine in right PV and four in left PV among the PVI group. Gap lengths in the roof region were longer than those in the bottom region (26.8 ± 11.8 vs. 14.5 ± 9.8 mm; P = 0.022), while those in right PV tended to longer than those in left PV (28.0 ± 15.3 vs. 16.8 ± 8.0 mm, P = 0.201). The entrances and exits of electrical conduction gaps were separated, especially in the roof region, indicating that epicardial conduction might contribute to gap formation. Identifying the bidirectional conduction gap might indicate the location and direction of epicardial conduction. Bidirectional activation maps for conduction gap at roof and bottom are shown. The length between the entrance and exit (gap length) is longer at roof line than bottom line (26.8 ± 11.8 vs. 14.6 ± 9.8 mm, P = 0.022).
- Open Access
- 28 April 2023
- Published by Hindawi Limited in Cardiology Research and Practice
- Vol. 2023, 1-7
Genetic Testing Enables the Diagnosis of Familial Hypercholesterolemia Underdiagnosed by Clinical Criteria: Analysis of Japanese Early-Onset Coronary Artery Disease Patients
Definitive diagnosis of familial hypercholesterolemia (FH) is paramount for the risk management of patients and their relatives. The present study aimed to investigate the frequency of gene variants contributing to low-density lipoprotein cholesterol (LDL-C) metabolism and their clinical relevance in patients with early-onset coronary artery disease (EOCAD). Among 63 consecutive patients with EOCAD (men LDLR variant had three-vessel disease, were on a statin prescription at baseline, and had stable LDL-C levels; however, the case showed a poor response to the intensification of medication after PCI. Approximately 3.8 of patients with EOCAD harbored variants of gene related to LDL-C metabolism; there were no notable indicators in the patients background or clinical course to diagnose FH. Given the difficulty in diagnosing FH based on clinical manifestations and family history, genetic testing could enable the identification of hidden risk factors and provide early warnings to their relatives.
- 28 April 2023
- Published by Hindawi Limited in Cardiology Research and Practice
- Vol. 2023, 1-7
Open AccessGenetic Testing Enables the Diagnosis of Familial Hypercholesterolemia Underdiagnosed by Clinical Criteria: Analysis of Japanese Early-Onset Coronary Artery Disease Patients
Definitive diagnosis of familial hypercholesterolemia (FH) is paramount for the risk management of patients and their relatives. The present study aimed to investigate the frequency of gene variants contributing to low-density lipoprotein cholesterol (LDL-C) metabolism and their clinical relevance in patients with early-onset coronary artery disease (EOCAD). Among 63 consecutive patients with EOCAD (men LDLR variant had three-vessel disease, were on a statin prescription at baseline, and had stable LDL-C levels; however, the case showed a poor response to the intensification of medication after PCI. Approximately 3.8 of patients with EOCAD harbored variants of gene related to LDL-C metabolism; there were no notable indicators in the patients background or clinical course to diagnose FH. Given the difficulty in diagnosing FH based on clinical manifestations and family history, genetic testing could enable the identification of hidden risk factors and provide early warnings to their relatives.
- 8 July 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 178, 43-51
Implications of QRS Prolongation in Patients With Atrial Fibrillation (from a Multicenter Outpatient Registry)
- 8 July 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 178, 43-51
Implications of QRS Prolongation in Patients With Atrial Fibrillation (from a Multicenter Outpatient Registry)
- Open Access
- 16 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (8) , 1730
Abnormal Liver Function Tests and Long-Term Outcomes in Patients Discharged after Acute Heart Failure
Abnormal liver function tests (LFTs) are known to be associated with impaired clinical outcomes in heart failure (HF) patients. However, this implication varies with each single LFT panel. We aim to evaluate the long-term outcomes of acute HF (AHF) patients by assessing multiple LFT panels in combination. From a prospective multicenter registry in Japan, 1158 AHF patients who were successfully discharged were analyzed (mean age, 73.9 ± 13.5 years; men, 58%). LFTs (i.e., total bilirubin, aspartate aminotransferase or alanine aminotransferase, and alkaline phosphatase) at discharge were assessed; borderline and abnormal LFTs were defined as 1 and ≥2 parameter values above the normal range, respectively. The primary endpoint was composite of all-cause death or HF readmission. At the time of discharge, 28.7% and 8.6% of patients showed borderline and abnormal LFTs, respectively. There were 196 (16.9%) deaths and 298 (25.7%) HF readmissions during a median 12.4-month follow-up period. The abnormal LFTs group had a significantly higher risk of experiencing the composite outcome (adjusted hazard ratio: 1.51, 95% confidence interval: 1.08–2.12, p = 0.017), whereas the borderline LFTs group was not associated with higher risk of adverse events when referenced to the normal LFTs group. Among AHF patients, the combined elevation of ≥2 LFT panels at discharge was associated with long-term adverse outcomes.
- 16 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (8) , 1730
Open AccessAbnormal Liver Function Tests and Long-Term Outcomes in Patients Discharged after Acute Heart Failure
Abnormal liver function tests (LFTs) are known to be associated with impaired clinical outcomes in heart failure (HF) patients. However, this implication varies with each single LFT panel. We aim to evaluate the long-term outcomes of acute HF (AHF) patients by assessing multiple LFT panels in combination. From a prospective multicenter registry in Japan, 1158 AHF patients who were successfully discharged were analyzed (mean age, 73.9 ± 13.5 years; men, 58%). LFTs (i.e., total bilirubin, aspartate aminotransferase or alanine aminotransferase, and alkaline phosphatase) at discharge were assessed; borderline and abnormal LFTs were defined as 1 and ≥2 parameter values above the normal range, respectively. The primary endpoint was composite of all-cause death or HF readmission. At the time of discharge, 28.7% and 8.6% of patients showed borderline and abnormal LFTs, respectively. There were 196 (16.9%) deaths and 298 (25.7%) HF readmissions during a median 12.4-month follow-up period. The abnormal LFTs group had a significantly higher risk of experiencing the composite outcome (adjusted hazard ratio: 1.51, 95% confidence interval: 1.08–2.12, p = 0.017), whereas the borderline LFTs group was not associated with higher risk of adverse events when referenced to the normal LFTs group. Among AHF patients, the combined elevation of ≥2 LFT panels at discharge was associated with long-term adverse outcomes.
- 15 October 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (11) , 1289-1294
Anatomical changes in the pulmonary veins and left atrium after cryoballoon ablation
Background: The anatomical changes in pulmonary veins (PVs) after cryoballoon ablation (CBA) are unclear. We aimed to determine the morphological changes in the PVs and left atrium (LA) along with the predictive factors for clinical PV stenosis.Methods: We analyzed data of 320 PVs from 80 patients who underwent CBA for atrial fibrillation (age: 62 ± 10 years, 59 males). All patients underwent pre‐ and post‐procedural cardiac computed tomography. We defined clinical PV stenosis when the cross‐sectional area decreased by more than 50%.Results: The average ostial PV area and LA volume decreased significantly after CBA (pre‐ vs post‐CBA; 2.4 ± 1.0 cm2 vs 2.3±1.1 cm2, P < .001, 75.0 ± 23.2 cm3 vs 70.7 ± 21.9 cm3, P < .001, respectively). There was a significant correlation between the reduction rates of the PV area and those of LA volume (R = 0.411, P < .001). The larger preoperative PV area and greater reduction in LA volume were associated with advanced PV narrowing. Clinical PV stenosis was observed in six PVs, was more common in females (male vs female; 0.8% vs 4.8%, P = .043), and tended to be more frequent in left PVs (left PVs vs right PVs; 3.1% vs 0.6%: P = .107), irrespective of the LA volume reduction.Conclusions: The significant reduction of the ostial PV area occurred after CBA, which correlated with the reduction rate of LA volume. The narrowing of the PV was partly produced by the LA volume reduction. Clinical PV stenosis was more common in females and tended to be more frequent in left PVs.
- 15 October 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (11) , 1289-1294
Anatomical changes in the pulmonary veins and left atrium after cryoballoon ablation
Background: The anatomical changes in pulmonary veins (PVs) after cryoballoon ablation (CBA) are unclear. We aimed to determine the morphological changes in the PVs and left atrium (LA) along with the predictive factors for clinical PV stenosis.Methods: We analyzed data of 320 PVs from 80 patients who underwent CBA for atrial fibrillation (age: 62 ± 10 years, 59 males). All patients underwent pre‐ and post‐procedural cardiac computed tomography. We defined clinical PV stenosis when the cross‐sectional area decreased by more than 50%.Results: The average ostial PV area and LA volume decreased significantly after CBA (pre‐ vs post‐CBA; 2.4 ± 1.0 cm2 vs 2.3±1.1 cm2, P < .001, 75.0 ± 23.2 cm3 vs 70.7 ± 21.9 cm3, P < .001, respectively). There was a significant correlation between the reduction rates of the PV area and those of LA volume (R = 0.411, P < .001). The larger preoperative PV area and greater reduction in LA volume were associated with advanced PV narrowing. Clinical PV stenosis was observed in six PVs, was more common in females (male vs female; 0.8% vs 4.8%, P = .043), and tended to be more frequent in left PVs (left PVs vs right PVs; 3.1% vs 0.6%: P = .107), irrespective of the LA volume reduction.Conclusions: The significant reduction of the ostial PV area occurred after CBA, which correlated with the reduction rate of LA volume. The narrowing of the PV was partly produced by the LA volume reduction. Clinical PV stenosis was more common in females and tended to be more frequent in left PVs.
- 1 April 2004
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 11 (3) , 273-279
Surgical experience of syringomyelia with reference to the findings of magnetic resonance imaging
- 1 April 2004
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 11 (3) , 273-279
Surgical experience of syringomyelia with reference to the findings of magnetic resonance imaging